EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Thromboembolism - Pipeline Review, H1 2017

  • ID: 4091146
  • Report
  • February 2017
  • 95 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cereno Scientific AB
  • F. Hoffmann-La Roche Ltd
  • Gamma Therapeutics Inc
  • GlycoMimetics Inc
  • Green Cross Corp
  • MORE
Thromboembolism - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H1 2017, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 2, 1, 3, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer AG
  • Cereno Scientific AB
  • F. Hoffmann-La Roche Ltd
  • Gamma Therapeutics Inc
  • GlycoMimetics Inc
  • Green Cross Corp
  • MORE
Introduction

Thromboembolism - Overview

Thromboembolism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Thromboembolism - Companies Involved in Therapeutics Development

Bayer AG

Cereno Scientific AB

China Biologic Products Inc

Daiichi Sankyo Company Ltd

F. Hoffmann-La Roche Ltd

Gamma Therapeutics Inc

GlycoMimetics Inc

Green Cross Corp

Ionis Pharmaceuticals Inc

Portola Pharmaceuticals Inc

The International Biotechnology Center (IBC) Generium

Verseon Corp

Thromboembolism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Thromboembolism - Drug Profiles

alteplase biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

antithrombin III (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

betrixaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edoxaban tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gammarin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GCC-2107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GMI-1271 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lysimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for Thromboembolism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAP-ANV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

valporic acid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YG-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Thromboembolism - Dormant Projects

Thromboembolism - Discontinued Products

Thromboembolism - Product Development Milestones

Featured News & Press Releases

Feb 08, 2017: FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting

Dec 23, 2016: Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban

Dec 08, 2016: Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE

Dec 06, 2016: New Analysis Shows People with Cancer Who Received XARELTO (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment

Dec 06, 2016: ASH 2016: Explaining the lower bleeding risk of Verseon’s anticoagulants

Nov 28, 2016: Portola Pharmaceuticals Announces Betrixaban Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition

Nov 28, 2016: Ten Abstracts on the Use of Bayer's Xarelto in Different Patient Populations Accepted for Presentation at ASH

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Nov 28, 2016: Research to Be Presented at ASH Annual Meeting Shows Verseon’s New Class of Anticoagulants Prevents Thrombosis While Preserving Platelet Function

Nov 14, 2016: Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically III Patients with Extended-Duration Betrixaban

Nov 07, 2016: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions

Nov 07, 2016: Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA (edoxaban) in Patients with Non-Valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions

Nov 03, 2016: Janssen To Present Data On Rivaroxaban At 58th American Society of Hematology Annual Meeting

Oct 25, 2016: Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients

Oct 23, 2016: Two New Real-World Studies Confirm Positive Efficacy and Safety Profile of XARELTO (rivaroxaban) in Treating and Preventing Blood Clots

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Thromboembolism, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Thromboembolism - Pipeline by Bayer AG, H1

Thromboembolism - Pipeline by Cereno Scientific AB, H1

Thromboembolism - Pipeline by China Biologic Products Inc, H1

Thromboembolism - Pipeline by Daiichi Sankyo Company Ltd, H1

Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H1

Thromboembolism - Pipeline by Gamma Therapeutics Inc, H1

Thromboembolism - Pipeline by GlycoMimetics Inc, H1

Thromboembolism - Pipeline by Green Cross Corp, H1

Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H1

Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H1

Thromboembolism - Pipeline by The International Biotechnology Center (IBC) Generium, H1

Thromboembolism - Pipeline by Verseon Corp, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Thromboembolism - Dormant Projects, H1

Thromboembolism - Discontinued Products, H1

List of Figures:

Number of Products under Development for Thromboembolism, H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • Bayer AG
  • Cereno Scientific AB
  • China Biologic Products Inc
  • Daiichi Sankyo Company Ltd
  • F. Hoffmann-La Roche Ltd
  • Gamma Therapeutics Inc
  • GlycoMimetics Inc
  • Green Cross Corp
  • Ionis Pharmaceuticals Inc
  • Portola Pharmaceuticals Inc
  • The International Biotechnology Center (IBC) Generium
  • Verseon Corp
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll